| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 767,20 | 767,90 | 15.04. | |
| 765,00 | 768,80 | 15.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 775,50 | 2 | |||
| 775,30 | 7 | |||
| 775,10 | 22 | |||
| 774,70 | 22 | |||
| 774,50 | 22 | |||
| 774,30 | 22 | |||
| 774,00 | 22 | |||
| 773,30 | 22 | |||
| 773,10 | 11 | |||
| 773,00 | 22 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/lly.htm [/URL] | ||||
| 22 | 771,40 | |||
| 11 | 771,30 | |||
| 22 | 770,80 | |||
| 7 | 769,00 | |||
| 2 | 768,80 | |||
| 2 | 768,60 | |||
| 22 | 748,60 | |||
| 22 | 748,50 | |||
| 1.078 | 0,000 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 1.188 | 0,146 | 174 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:35:31 | 772,20 | 22 |
| 17:29:00 | 771,00 | 1 |
| 17:25:32 | 770,00 | 4 |
| 17:25:29 | 770,00 | 2 |
| 17:16:21 | 773,40 | 1 |
| 17:15:37 | 773,60 | 8 |
| 17:10:08 | 773,60 | 11 |
| 17:10:08 | 773,60 | 41 |
| 17:09:45 | 772,90 | 3 |
| 17:08:10 | 771,40 | 6 |
| 17:01:59 | 769,50 | 8 |
| 17:01:59 | 769,50 | 2 |
| 16:59:15 | 771,20 | 3 |
| 16:56:31 | 771,70 | 7 |
| 16:53:41 | 774,70 | 2 |
| 16:53:03 | 774,80 | 14 |
| 16:53:03 | 774,80 | 6 |
| 16:53:01 | 775,00 | 1 |
| 16:53:01 | 775,00 | 2 |
| 16:53:01 | 775,00 | 1 |
| Tagesumsatz Xetra | -20,70 -2,61 % | 744 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust | 66 | The Motley Fool | ||
| Mi | FDA asks Lilly to evaluate obesity pill's liver risk | 10 | BioPharma Dive | ||
| Mi | Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors | 11 | MedCity News | ||
| Mi | BMO bestätigt "Outperform" für Eli Lilly: Studienauflagen für Foundayo gelten als unproblematisch | 19 | Investing.com Deutsch | ||
| ELI LILLY Aktie jetzt für 0€ handeln | |||||
| Mi | BMO reiterates Eli Lilly stock Outperform on manageable post-marketing requirements | 4 | Investing.com |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| Mi | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| Mi | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| Mi | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| Mi | Boehringer Ingelheim Limited: Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | GlobeNewswire (Europe) | Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase... ► Artikel lesen |